Vizen Life Sciences Pvt Ltd

Save the date and register to attend the 2024 FDA Oncology Center of Excellence Pediatric Advocacy Forum on Oct 15, 2024. In-person and virtual attendance options. Registration is free. Event details: https://lnkd.in/eiAAUv5A

SAVE THE DATE: FDA is hosting a public workshop on Nov. 6, 2024, titled “Accreditation Scheme for Conformity Assessment and Use of Chemical Analysis to Support Biocompatibility of Medical Devices.” The purpose of this workshop is to discuss the possible expansion of the Accreditation Scheme for Conformity Assessment (ASCA) program to include chemical analysis to support biocompatibility of medical devices. The registration deadline is Oct. 30, 2024. Join FDA: https://lnkd.in/e62qCAmV

📢 Medicines and Healthcare products Regulatory Agency has approved the first generic raltegravir medicines to treat adult and paediatric patients infected by HIV Raltegravir works by stopping HIV-produced enzyme HIV integrase (which enables multiplication of the virus in cells within the body) from working. When used with other medicines, it may reduce the amount of HIV in the patient’s blood and increase the patient’s CD4-cell count (a type of white blood cell that plays an important role in maintaining a healthy immune system). Reducing the amount of HIV in the blood may improve the functioning of the immune system, meaning the body may fight infection better. Our Deputy Director of Innovative Medicines, Shirley Hopper, said: "“Ensuring timely access to generic medicines is a key priority for us. “Appropriate data have been provided to assure us that these medicines are the same as, and considered interchangeable with an already licensed reference medicine, called Isentress. “As with all products, we will keep the safety of raltegravir under close review.’’ Find out more ➡️ https://bit.ly/3LxQJwc

⚠️ Food recall from Canadian Food Inspection Agency ⚠️ Various Silk and Great Value brand beverages have been recalled due to Listeria monocytogenes. 🚨 To see all the affected products, click here: https://bit.ly/3YgH6tJ ⬇️ Searching for the codes but not sure where to look? Check out the image below! It shows where the best before date and product codes are printed on your carton. All recalled products should be returned to the location where they were purchased or thrown out.

Public interest around Glucagon-Like Peptide-1 (#GLP1) receptor agonists, mostly around their use for weight-loss, has grown considerably in the last years. From academic and medical discussions to social media, from gossip to celebrity endorsements, GLP-1s are everywhere. 🗨 🎙 Join our Instagram LIVE with Dr. Bart Van der Schueren, EMA expert and obesity specialist. We’ll explore GLP-1s — from what they are and how they work to how they are used in clinical practice. 📅 Tune in on Monday, 22 July at 18:00 on the joint Instagram account @one_healthenv_eu managed with our sister agencies European Food Safety Authority (EFSA), European Environment Agency, European Centre for Disease Prevention and Control (ECDC) and European Chemicals Agency and get your questions answered! #WeightLoss #Obesity #Diabetes #HealthTalk

The Egyptian Drug Authority (EDA) published the most Pharmacology warnings till 14-7-2024 #Pharmacovigilance #Regulatory_affairs

The EMA’s safety committee, PRAC, has recommended the suspension of marketing authorizations for medicinal products containing 17-hydroxyprogesterone caproate (17-OHPC) throughout the European Union (EU). This decision follows findings from a large epidemiological study that suggest a potential increased risk of cancer in offspring exposed to 17-OHPC in utero. While this risk is suggested, it cannot be definitively confirmed due to limitations within the study.

To support the Government’s reforms to the regulation of vaping goods in Australia, transitional arrangements have been put in place. These arrangements allow businesses holding vaping goods that can no longer be supplied in Australia to divest themselves of these products without committing a supply or possession offence. The Business Surrender Scheme allows businesses to surrender specified quantities of vaping goods that were lawful prior to 1 July 2024 but that are no longer lawful following the commencement of the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Act 2024 on 1 July 2024. The scheme is available to businesses possessing more than: • 280 vaping devices • 1,800 vaping accessories • 12,000mL of vaping substance. Businesses that wish to participate must notify the TGA before 1 September 2024 by email to vapereturn@health.gov.au. The scheme is available to pharmacy and non-pharmacy retailers, wholesalers, manufacturers, importers, exporters, transport or storage providers. Read more: https://lnkd.in/gKuMn7nA

New AusPAR for Spevigo (spesolimab) has been approved for the treatment of generalised pustular psoriasis, a rare but severe form of psoriasis that involves flares of widespread, non-infectious, macroscopically visible pustules. Read more: https://lnkd.in/g95RKfdV

We’re delighted to welcome Prakash reddy Aripirala to the Vizen Life Sciences Pvt Ltd family. Mr Prakash's impressive experience will be a tremendous asset to our team. We’re looking forward to collaborating and reaching new heights together. Welcome onboard Mr Prakash Reddy!